Effects of antihypertensive drugs on capillary rarefaction in spontaneously hypertensive rats: Intravital microscopy and histologic analysis

Journal of Cardiovascular Pharmacology

Volumn 51, Issue 4, 2008, Pages 402-409

  Sabino, Bruno ^a   Lessa, Marcos A ^a   Nascimento, Alessandro R ^a   Rodrigues, Carlos A B ^b   Henriques, Maria Das Graças ^b   Garzoni, Luciana R ^a   Levy, Bernard I ^c   Tibiriçá, Eduardo ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Medicines and Drugs Technology Institute Fiocruz   (Brazil)

^c HÔPITAL LARIBOISIÈRE   (France)

Author keywords

blocker; ACE inhibitor; AT1 receptor antagonist; Calcium channel blocker; Capillary rarefaction; Intravital capillaroscopy; SHR

Indexed keywords

ATENOLOL; ENALAPRIL; LOSARTAN; NIFEDIPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE THERAPY; ARTICLE; CAPILLARY DENSITY; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG EFFECT; ESSENTIAL HYPERTENSION; HISTOLOGY; MALE; MICROCIRCULATION; MICROSCOPY; MUSCLE CAPILLARY; NONHUMAN; PRIORITY JOURNAL; RAT; SKELETAL MUSCLE; SKIN CAPILLARY; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BLOOD PRESSURE; CAPILLARIES; DISEASE MODELS, ANIMAL; ENALAPRIL; HEART VENTRICLES; HYPERTENSION; LOSARTAN; MALE; MICROCIRCULATION; MICROSCOPY, VIDEO; MUSCLE, SKELETAL; NIFEDIPINE; RATS; RATS, INBRED SHR; RATS, INBRED WKY; SKIN;

EID: 42449102706     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181673bc5     Document Type: Article

References (49)

1. Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21:1983-1992.
2. Cohuet G, Struijker-Boudier H. Mechanisms of target organ damage caused by hypertension: therapeutic potential. Pharmacol Ther. 2006;111: 81-98.
3. Vicaut E. Microcirculation and arterial hypertension. Drugs. 1999;58: 1-10.
4. Struijker Boudier HA, le Noble JL, Messing MW, et al. The microcirculation and hypertension. J Hypertens Suppl. 1992;10: S147-156.
5. Antonios TF, Singer DR, Markandu ND, et al. Structural skin capillary rarefaction in essential hypertension. Hypertension. 1999;33:998-1001.
6. Debbabi H, Uzan L, Mourad JJ, et al. Increased skin capillary density in treated essential hypertensive patients. Am J Hypertens. 2006;19: 477-483.
7. Schiffrin EL. Reactivity of small blood vessels in hypertension: relation with structural changes. State of the art lecture. Hypertension. 1992;19: II1-9.
8. Feihl F, Liaudet L, Waeber B, et al. Hypertension: a disease of the microcirculation? Hypertension. 2006;48:1012-1017.
9. Greene AS, Tonellato PJ, Lui J, et al. Microvascular rarefaction and tissue vascular resistance in hypertension. Am J Physiol. 1989;256:H126-31.
10. Levy B. Importance of improving tissue perfusion during treatment of hypertension. J Hypertens Suppl. 2006;24:S6-9.
11. Battegay EJ, de Miguel LS, Petrimpol M, et al. Effects of antihypertensive drugs on vessel rarefaction. Curr Opin Pharmacol. 2007;7: 151-157.
12. Levy BI, Ambrosio G, Pries AR, et al. Microcirculation in hypertension: a new target for treatment? Circulation. 2001;104:735-740.
13. Izzard AS, Heagerty AM. Hypertension and the vasculature: arterioles and the myogenic response. J Hypertens. 1995;13:1-4.
14. Serne EH, Gans RO, ter Maaten JC, et al. Impaired skin capillary recruitment in essential hypertension is caused by both functional and structural capillary rarefaction. Hypertension. 2001;38:238-242.
15. Antonios TF, Singer DR, Markandu ND, et al. Rarefaction of skin capillaries in borderline essential hypertension suggests an early structural abnormality. Hypertension. 1999;34:655-658.
16. Noon JP, Walker BR, Webb DJ, et al. Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure. J Clin Invest. 1997;99:1873-1879.
17. Hern S, Mortimer PS. Visualization of dermal blood vessels- capillaroscopy. Clin Exp Dermatol. 1999;24:473-478.
18. Agabiti-Rosei E. [Structural and functional changes of the microcirculation in hypertension: influence of pharmacological therapy]. Drugs. 2003;63:19-29.
19. Mourad JJ, Laville M. Is hypertension a tissue perfusion disorder? Implications for renal and myocardial perfusion. J Hypertens Suppl. 2006; 24:S10-16.
20. Silvestre JS, Bergaya S, Tamarat R, et al. Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway. Circ Res. 2001;89:678-683.
21. Ebrahimian TG, Tamarat R, Clergue M, et al. Dual effect of angiotensin-converting enzyme inhibition on angiogenesis in type 1 diabetic mice. Arterioscler Thromb Vasc Biol. 2005;25:65-70.
22. Gohlke P, Kuwer I, Schnell A, et al. Blockade of bradykinin B2 receptors prevents the increase in capillary density induced by chronic angiotensin-converting enzyme inhibitor treatment in stroke-prone spontaneously hypertensive rats. Hypertension. 1997;29:478-482.
23. Mattfeldt T, Mall G, Gharehbaghi H, et al. Estimation of surface area and length with the orientator. J Microsc. 1990;159:301-117.
24. Mattfeldt T, Mobius HJ, Mall G. Orthogonal triplet probes: an efficient method for unbiased estimation of length and surface of objects with unknown orientation in space. J Microsc. 1985;139:279-289.
25. Hutchins PM, Darnell AE. Observation of a decreased number of small arterioles in spontaneously hypertensive rats. Circ Res. 1974;24:1161-1165.
26. Chen, II, Prewitt RL, Dowell RF. Microvascular rarefaction in spontaneously hypertensive rat cremaster muscle. Am J Physiol. 1981; 241:H306-310.
27. Struyker-Boudier HA le Noble JL, Slaaf DW, et al. Microcirculatory changes in cremaster muscle during early spontaneous hypertension in the rat. J Hypertens Suppl. 1988;6:S185-187.
28. Prewitt RL, Chen, II, Dowell R. Development of microvascular rarefaction in the spontaneously hypertensive rat. Am J Physiol. 1982; 243:H243-251.
29. Melo RM, Martinho E Jr, Michelini LC. Training-induced, pressure-lowering effect in SHR: wide effects on circulatory profile of exercised and nonexercised muscles. Hypertension. 2003;42:851-857.
30. Crisman RP, Rittman B, Tomanek RJ. Exercise-induced myocardial capillary growth in the spontaneously hypertensive rat. Microvasc Res. 1985;30:185-194.
31. Minami N, Li Y, Guo Q, et al. Effects of angiotensin-converting enzyme inhibitor and exercise training on exercise capacity and skeletal muscle. J Hypertens. 2007;25:1241-1248.
32. Clozel JP, Kuhn H, Hefti F. Effects of chronic ACE inhibition on cardiac hypertrophy and coronary vascular reserve in spontaneously hypertensive rats with developed hypertension. J Hypertens. 1989;7:267-275.
33. Olivetti G, Cigola E, Lagrasta C, et al. Spirapril prevents left ventricular hypertrophy, decreases myocardial damage and promotes angiogenesis in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1993;21:362-370.
34. Unger T, Mattfeldt T, Lamberty V, et al. Effect of early onset angiotensin converting enzyme inhibition on myocardial capillaries. Hypertension. 1992;20:478-482.
35. Rakusan K, Cicutti N, Maurin A, et al. The effect of treatment with low dose ACE inhibitor and/or diuretic on coronary microvasculature in stroke-prone spontaneously hypertensive rats. Microvasc Res. 2000;59: 243-254.
36. Toblli JE, Cao G, DeRosa G, et al. Angiotensin-converting enzyme inhibition and angiogenesis in myocardium of obese Zucker rats. Am J Hypertens. 2004;17:172-180.
37. Richer C, Doussau MP, Giudicelli JF. Systemic and regional hemodynamic profile of five angiotensin I converting enzyme inhibitors in the spontaneously hypertensive rat. Am J Cardiol. 1987;59:12D-17D.
38. Carey RM. Update on the role of the AT2 receptor. Curr Opin Nephrol Hypertens. 2005;14:67-71.
39. Munk VC, Sanchez de Miguel L, Petrimpol M, et al. Angiotensin II induces angiogenesis in the hypoxic adult mouse heart in vitro through an AT2-B2 receptor pathway. Hypertension. 2007;49:1178-1185.
40. Sabri A, Samuel JL, Marotte F, et al. Microvasculature in angiotensin II-dependent cardiac hypertrophy in the rat. Hypertension. 1998;32:371-375.
41. Schieffer B, Wirger A, Meybrunn M, et al. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation. 1994;89:2273-2282.
42. van Zwieten PA, Pfaffendorf M. Similarities and differences between calcium antagonists: pharmacological aspects. J Hypertens Suppl. 1993; 11:S3-11.
43. Heap SJ, Fulgenzi GL, Hudlicka O. Microcirculation in rat soleus muscle after eccentric exercise: the effect of nifedipine. Eur J Appl Physiol. 2006; 97:687-694.
44. Hudlicka O. What makes blood vessels grow? J Physiol. 1991;444:1-24.
45. Christensen KL, Jespersen LT, Mulvany MJ. Development of blood pressure in spontaneously hypertensive rats after withdrawal of long-term treatment related to vascular structure. J Hypertens. 1989;7:83-90.
46. Schiffrin EL, Deng LY, Larochelle P. Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension. 1994;23:83-91.
47. Thybo NK, Stephens N, Cooper A, et al. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension. 1995;25:474-481.
48. Christensen KL, Mulvany MJ. Vasodilatation, not hypotension, improves resistance vessel design during treatment of essential hypertension: a literature survey. J Hypertens. 2001;19:1001-1006.
49. Volpert OV, Ward WF, Lingen MW, et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest. 1996; 98:671-679.